BioCryst Pharmaceuticals, Inc. (BCRX:NASDAQ) closed at $8.05 on October 14, 2026, down 0.25% on the day. The stock trades 28.3% below its 52-week high of $11.22 and 29.2% above its 52-week low of $6.23. Over the past year, it gained 18.2%. BioCryst Pharmaceuticals, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -3.71% | -1.35% | -13.35% | -12.40% | +18.21% |
In 252 trading sessions since October 14, 2025, BCRX closed higher on 122 days (48%). Its best day was March 16, 2026 (+13.14%) and its worst was September 8, 2026 (-8.94%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the Universi...
Find more stocks like BCRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.